- Conditions
- Renal Transplantation, Aging
- Interventions
- 23 valent pneumococcal polysaccharide vaccine, 13 valent conjugated pneumococcal vaccine, Peripheral blood sample
- Drug · Biological · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Charleston, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumococcal Disease
- Interventions
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 605 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 61
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • La Puente, California + 39 more
- Conditions
- Vaccine, Pneumococcal Disease
- Interventions
- Pneumococcal Vaccine
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pneumococcal Disease
- Interventions
- Experimental 20-valent pneumococcal conjugate vaccine (20vPnC), Saline, Influenza vaccine
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,796 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 63
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 53 more
- Conditions
- Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
- Interventions
- Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 4,538 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more
- Conditions
- Leukemia
- Interventions
- Sargramostim (GM-CSF), Pneumococcal Vaccine
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pneumococcal Disease
- Interventions
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 225 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 35
- States / cities
- Washington D.C., District of Columbia • Miami, Florida • Chamblee, Georgia + 18 more
- Conditions
- Study is Open to Seniors Age 50 or Older
- Interventions
- Pharmacist Pneumococcal Vaccine Program (PPVP)
- Behavioral
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Sickle Cell Disease
- Interventions
- PCV21, 20vPCV
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Omaha, Nebraska • New Brunswick, New Jersey + 1 more
- Conditions
- HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
- Interventions
- Prevnar-13
- Biological
- Lead sponsor
- VA Eastern Colorado Health Care System
- Federal
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Aging
- Interventions
- vaccine
- Other
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Pneumococcal Disease
- Interventions
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Estero, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 16 more
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™, PNEUMOVAX™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Orlando, Florida • West Palm Beach, Florida • Houston, Texas
- Conditions
- Pneumococcal Infection
- Interventions
- V116, Placebo, PCV15, PPSV23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 518 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 8
- States / cities
- Mesa, Arizona • Hialeah, Florida • West Palm Beach, Florida + 5 more
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Interventions
- PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
- Biological
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pneumonia, Pneumococcal
- Interventions
- V116, PCV15, PPSV23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 717 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tempe, Arizona + 12 more
- Conditions
- HIV Infections
- Interventions
- Lopinavir/Ritonavir, Lamivudine/Zidovudine, Tenofovir disoproxil fumarate, Pneumococcal Vaccine, Polyvalent (23-valent), Lamivudine, Stavudine, Zidovudine, Didanosine, Lyme Disease Vaccine Recombinant OspA, Haemophilus B Conjugate Vaccine
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2006
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio
- Conditions
- Healthy
- Interventions
- pneumococcal vaccination (Pneumovax)
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™, PNEUMOVAX™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 13
- States / cities
- Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more
- Conditions
- Infections, Streptococcal
- Interventions
- Pneumococcal vaccine GSK2189242A, Placebo, Prevnar 13®, PedvaxHIB®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 1,806 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 5
- States / cities
- Chinle, Arizona • Fort Defiance, Arizona • Whiteriver, Arizona + 2 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, PCV20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Guntersville, Alabama • Phoenix, Arizona • Huntington Beach, California + 17 more
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™, PNEUMOVAX™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 1,515 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 38
- States / cities
- Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more
- Conditions
- Infections, Meningococcal
- Interventions
- Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 1,196 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more
- Conditions
- Pneumococcal Immunization
- Interventions
- Pneumococcal Conjugate Vaccine, Prevnar 13®
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 19 Years to 49 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Metairie, Louisiana • Newark, New Jersey